Zydus Receives EIR for Jarod Injectable Facility from USFDA
Filing Summary
Zydus Lifesciences Ltd has received an Establishment Inspection Report (EIR) from the USFDA for its injectable facility in Jarod, Vadodara. The inspection, conducted from August 25 to September 5, 2025, resulted in a classification of Voluntary Action Indicated (VAI). This follows a Warning Letter issued by the USFDA on August 29, 2024. The disclosure aligns with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Zydus Lifesciences Ltd has announced the receipt of an Establishment Inspection Report (EIR) from the USFDA for its injectable facility located in Jarod, Vadodara. The inspection was conducted from August 25 to September 5, 2025.
The facility has been classified as Voluntary Action Indicated (VAI) following the inspection. This inspection was a follow-up to a Warning Letter issued by the USFDA on August 29, 2024. The company has disclosed this information in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Zydus Lifesciences Ltd focuses on the development and manufacturing of a wide range of pharmaceutical products. The company is involved in research and development activities aimed at producing innovative healthcare solutions. Zydus continues to expand its global presence and enhance its product portfolio in the pharmaceutical industry.